Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Implantable stimulator aims to stop blood pressure swings in spinal cord injury

NCT ID NCT07147296

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an implanted spinal cord stimulator (ARC-IM System) to help people with chronic spinal cord injury manage dangerously low blood pressure and fainting. Sixty participants will receive the implant and be randomly assigned to active or sham stimulation for 3 months, then all receive active therapy. The goal is to see if the device safely improves blood pressure stability and reduces symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ARC-IM System (implanted spinal cord stimulator)
What this could lead to
If it works, this could provide a long-term, at-home treatment to stabilize blood pressure and reduce fainting episodes for people with chronic spinal cord injury.
What could go wrong
This is a pivotal trial but still involves surgery and device risks. The control group receives a sham stimulation, and long-term benefits beyond 6 months are not yet known.
Why investors are watching

Onward Medical N.V. is a micro-cap company, and its subsidiary Onward Medical, Inc. runs this pivotal trial of the ARC-IM System, a device implanted to manage blood pressure instability in people with chronic spinal cord injury. The trial randomizes 60 participants 2:1 to active or sham therapy for 3 months, then gives everyone the active version. For a company this small, the 3-month primary outcome, which combines patient-reported symptoms and seated blood pressure, will largely determine whether the device can move toward approval and become a commercial product.

If it works: A positive result could support regulatory approval for the ARC-IM System, giving Onward Medical its first marketable product and a revenue source. It would also validate the technology for a condition with few treatment options, which may attract partners or funding.

If it fails: The trial could fail to show a meaningful difference from the sham, or the company could face delays in enrollment or follow-up. Trials fail often, and for a micro-cap with no approved product, a negative or delayed readout could leave the company without a clear path forward.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 years or above, and no older than 75 years at the time of enrollment. 2. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria. 3. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication. 4. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score 5. A Spinal cord injury at the neurologic level between C2 and T6 inclusive. 6. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D. 7. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry. 8. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation 9. Stable medical, physical, and psychological condition as considered by the investigators. 10. Stable dose of blood pressure medication for 30-days prior to enrollment into the study . Stability will be defined as no changes to medication regimens based on treating physician instructions. 11. Subjects who are on long-term antihypertensive treatment must discontinue these medications no less than 30 days prior to enrollment in the study. This requirement does not apply to antihypertensive agents administered for the acute management of autonomic dysreflexia (AD) 12. If the subject requires daily continuous support from a personal caregiver, the presence of a caregiver during the study visits is mandatory. 13. Willing and able to provide informed consent. 14. Stated willingness to comply with all study procedures and availability for the duration of the study. 15. Willing and able to comply with the instructions for use, operate the study devices, and comply with this clinical investigation plan Exclusion Criteria: 1. Subject has an autoimmune etiology of spinal cord dysfunction/injury. 2. Subject has diseases and conditions that would increase the morbidity and mortality of the surgical procedures required by the study. 3. Subject has a history of physiologic hypotension prior to SCI 4. Subject has a history of unexpected blood pressure instability related to medications 5. Inability to withhold antiplatelet/anticoagulation agents perioperatively. 6. History of myocardial infarction or cerebrovascular event within the past 6 months. or 7. History of chronic/recurrent severe cardiac arrythmias (e.g., ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block) 8. Evidence of clinically significant underlying cardiac conditions on Holter monitoring performed at screening including but not limited to arrhythmias (e.g., atrial fibrillation, ventricular tachycardia), 9. Evidence of ischemic changes or prolonged QT interval (QTc \> of 450 ms for males and 470 ms for females) identified on EKG during screening, 10. Subjects with a known diagnosis of heart failure, including but not limited to New York Heart Association (NYHA) Class I-IV, or with evidence of clinically significant left ventricular dysfunction (ejection fraction \< 40%) as determined by echocardiogram during screening or within the past 6 months, 11. Current renal/kidney, hepatic, or other concomitant disorders deemed severe by the Investigator including those ones that could be linked to severe autonomic dysreflexia. 12. Requires continuous ventilator support. 13. Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicate lead placement 14. Known allergic reaction to implanted materials 15. Requires continuous/frequent/any transcutaneous spinal cord stimulation treatment. 16. Has any active implanted medical device (e.g. baclofen pump, pacemaker). 17. Inability to receive a pre-operative MRI. 18. Female subject who is pregnant, breastfeeding or planning to become pregnant or breastfeed. Women of child-bearing potential must have a negative pregnancy test completed at baseline visit per site standard test. 19. Presence of pressure sore at time of screening or baseline graded stage 3 or 4 . 20. Subject is enrolled or intends to participate in another clinical drug and/or device study or registry that may interfere with the results of this study, as determined by ONWARD Medical personnel. 21. Presence of other anatomic or comorbid conditions, or other medical, social, or psychologic conditions such as severe uncontrolled neuropathic pain, depression, history of alcohol or substance abuse, history of schizophrenia or psychotic illness, severe personality disorder or other significant psychiatric or cognitive disorders that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    13 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Columbia University Irving Medical Center/ New York-Presbyterian Hospital

    RECRUITING

    New York, New York, 10032, United States

  • Craig Hospital

    RECRUITING

    Englewood, Colorado, 80113, United States

  • ICORD

    RECRUITING

    Vancouver, British Columbia, V5Z 1N1, Canada

  • James J. Peters VA Medical Center

    RECRUITING

    The Bronx, New York, 10468, United States

  • Kennedy krieger Institute

    RECRUITING

    Baltimore, Maryland, 21205, United States

  • Mayo clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Email: •••••@•••••

  • Shepherd Center / Emory University

    RECRUITING

    Atlanta, Georgia, 30309, United States

  • Spaulding Rehabilitation

    RECRUITING

    Cambridge, Massachusetts, 02138, United States

  • University of Arkansas for medical Sciences

    RECRUITING

    Little Rock, Arkansas, 72205, United States

    Contact Email: •••••@•••••

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • UofL Health - Frazier Rehabilitation Institute

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • VA Louisville

    RECRUITING

    Louisville, Kentucky, 40245, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.